On World Arthritis Day, TOGETHER-PsA data and 3 rheumatology/derm experts frame GLP-1 agonists as a promising — but not yet proven — adjunct therapy.
|Slideshows|August 1, 2018
Looking for a Good Single Measure in Psoriatic Arthritis
An international research team compared the Physician’s Global Assessment with separate evaluations of skin and musculoskeletal disease activity in PsA.
Advertisement
Reference1. Cauli A, Gladman DD, Mathieu A, et al; for the GRAPPA 3PPsA Study Group. Physician’s Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. J Rheumatol. 2018 Jun 15. pii: jrheum.171183. doi: 10.3899/jrheum.171183. [Epub ahead of print]
Advertisement
Related to this article
At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.
Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.
Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for PsA.
In a large real-world PsA cohort, higher BMI reduced the odds of minimal disease activity, especially with TNF inhibitors other than infliximab.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
Baseline structural damage accounted for most of the variance in placebo-arm radiographic progression across 6 PsA trials.
Ruderman discusses how Northwestern's joint dermatology-rheumatology clinic shapes diagnosis and treatment of psoriatic disease.
Advertisement
Advertisement